New drug dance: alternating two powerful meds may boost survival in Hard-to-Treat breast cancer
NCT ID NCT07151586
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 36 times
Summary
This phase 2 trial tests whether alternating two targeted chemotherapy drugs—sacituzumab govitecan and trastuzumab deruxtecan—can help people with HER2-low metastatic triple-negative breast cancer live longer. About 260 participants will be randomly assigned to receive either the alternating two-drug regimen or sacituzumab govitecan alone. The study aims to see if switching between drugs delays cancer growth and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER 2 LOW-EXPRESSING BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gustave Roussy
Villejuif, 94800, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
institut Paoli calmette
Marseille, 13009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab govitecan (Trodelvy) and trastuzumab deruxtecan (Enhertu)
What this could lead to
If successful, this alternating drug regimen could improve survival for people with HER2-low metastatic triple-negative breast cancer compared to standard single-drug therapy.
What could go wrong
This is a phase 2 trial, so results are still early. The alternating schedule may not prove better than the current treatment, and side effects from combining two strong drugs could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.